ReceptorBio is an early-stage biopharmaceutical company that is developing orally active pharmaceuticals for the treatment of insulin resistance, type 2 diabetes mellitus (T2D), and the ‘Metabolic Syndrome’, all of which are linked to a markedly increased risk of cardiovascular disease and other disorders. The Company’s initial focus will be on the clinical development of its lead compound, RB101, a late stage pre-clinical compound that activates the tyrosine kinase domain of the insulin receptor (IR), a recognized drug target for T2D. Activation of the IR is required to mediate insulin’s physiological effects on the control of blood glucose and other processes. Currently, there are no FDA-approved drugs with this mechanism of action. ReceptorBio believes its novel agent is first in class, with a mechanism of action that is compatible for use both as a single agent and in combination with existing drugs for T2D.
Company Details
- Founded
- -
- Address
- Redwood City, Ca 94061, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.receptorbiohq.com
- Keywords
- Type 2 Diabetes.
- HQ
- Redwood City, CA
- Competitors
- Bristol Myers Squibb.
Receptorbio Questions
Receptorbio's website is http://www.receptorbiohq.com
Receptorbio's LinkedIn profile is https://www.linkedin.com/company/receptorbio
Receptorbio's industry is
Pharmaceutical Manufacturing
Receptorbio's top competitors are
Bristol Myers Squibb.
Receptorbio's categories are Pharmaceutical Manufacturing
Receptorbio's founding year is 2008
